Lei Liu

Lei Liu

Auto-generated profile, based on publicly available information

Lei Liu

Department of Neurology, Mass General Brigham, Boston, MA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in Cell
Verified
Journal Article
Closed access
CCChun-Cheih Chao
Chun-Cheih Chao
CGCristina Gutiérrez-Vázquez
Cristina Gutiérrez-Vázquez
VRVeit Rothhammer
Veit Rothhammer
LMLior Mayo
Lior Mayo
MWMichael A. Wheeler
Michael A. Wheeler
FQFrancisco J. Quintana
Francisco J. Quintana

16 January 2023 in npj Parkinson's Disease
Verified
Journal Article
Open access
PDF file
NRNagendran Ramalingam
Nagendran Ramalingam
SJShan-Xue Jin
Shan-Xue Jin
TMTim E. Moors
Tim E. Moors
LFLuis Fonseca-Ornelas
Luis Fonseca-Ornelas
KSKazuma Shimanaka
Kazuma Shimanaka
UDUlf Dettmer
Ulf Dettmer
In Parkinson’s disease and other synucleinopathies, the elevation of α-synuclein phosphorylated at Serine129 (pS129) is a widely cited marker of pathology. However, the physiological role for pS129 has remained undefined. Here we use multiple approaches to show for the first time that pS129 functions as a physiological regulator of neuronal activity. Neuronal activity triggers a sustained increase of pS129 in cultured neurons (200% within 4 h). In accord, brain pS129 is elevated in environmentally enriched mice exhibiting enhanced long-term potentiation. Activity-dependent α-synuclein phosphorylation is S129-specific, reversible, confers no cytotoxicity, and accumulates at synapsin-containing presynaptic boutons. Mechanistically, our findings are consistent with a model in which neuronal stimulation enhances Plk2 kinase activity via a calcium/calcineurin pathway to counteract PP2A phosphatase activity for efficient phosphorylation of membrane-bound α-synuclein. Patch clamping of rat SNCA−/− neurons expressing exogenous wild-type or phospho-incompetent (S129A) α-synuclein suggests that pS129 fine-tunes the balance between excitatory and inhibitory neuronal currents. Consistently, our novel S129A knock-in (S129AKI) mice exhibit impaired hippocampal plasticity. The discovery of a key physiological function for pS129 has implications for understanding the role of α-synuclein in neurotransmission and adds nuance to the interpretation of pS129 as a synucleinopathy biomarker.

9 April 2025 in Nature
Verified
Journal Article
Closed access
PDF file
KKKimitoshi Kimura
Kimitoshi Kimura
ASAyshwarya Subramanian
Ayshwarya Subramanian
ZYZhuoran Yin
Zhuoran Yin
AKAhad Khalilnezhad
Ahad Khalilnezhad
YWYufan Wu
Yufan Wu
VKVijay K. Kuchroo
Vijay K. Kuchroo

9 January 2019 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
LLLei Liu
Lei Liu
LDLi Ding
Li Ding
MRMatteo Rovere
Matteo Rovere
MWMichael S. Wolfe
Michael S. Wolfe
DSDennis J. Selkoe
Dennis J. Selkoe
Intramembrane proteolysis of transmembrane substrates by the presenilin–γ-secretase complex is preceded and regulated by shedding of the substrate’s ectodomain by α- or β-secretase. We asked whether β- and γ-secretases interact to mediate efficient sequential processing of APP, generating the amyloid β (Aβ) peptides that initiate Alzheimer’s disease. We describe a hitherto unrecognized multiprotease complex containing active β- and γ-secretases. BACE1 coimmunoprecipitated and cofractionated with γ-secretase in cultured cells and in mouse and human brain. An endogenous high molecular weight (HMW) complex (∼5 MD) containing β- and γ-secretases and holo-APP was catalytically active in vitro and generated a full array of Aβ peptides, with physiological Aβ42/40 ratios. The isolated complex responded properly to γ-secretase modulators. Alzheimer’s-causing mutations in presenilin altered the Aβ42/40 peptide ratio generated by the HMW β/γ-secretase complex indistinguishably from that observed in whole cells. Thus, Aβ is generated from holo-APP by a BACE1–γ-secretase complex that provides sequential, efficient RIP processing of full-length substrates to final products.

27 November 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
JCJasmeer P. Chhatwal
Jasmeer P. Chhatwal
ASAaron P. Schultz
Aaron P. Schultz
YDYifan Dang
Yifan Dang
BOBeth Ostaszewski
Beth Ostaszewski
LLLei Liu
Lei Liu
DSDennis J. Selkoe
Dennis J. Selkoe
The availability of blood-based assays detecting Alzheimer’s disease (AD) pathology should greatly accelerate AD therapeutic development and improve clinical care. This is especially true for markers that capture the risk of decline in pre-symptomatic stages of AD, as this would allow one to focus interventions on participants maximally at risk and at a stage prior to widespread synapse loss and neurodegeneration. Here we quantify plasma concentrations of an N-terminal fragment of tau (NT1) in a large, well-characterized cohort of clinically normal elderly who were followed longitudinally. Plasma NT1 levels at study entry (when all participants were unimpaired) were highly predictive of future cognitive decline, pathological tau accumulation, neurodegeneration, and transition to a diagnosis of MCI/AD. These predictive effects were particularly strong in participants with even modestly elevated brain β-amyloid burden at study entry, suggesting plasma NT1 levels capture very early cognitive, pathologic and neurodegenerative changes along the AD trajectory.

8 November 2018 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
SLShaomin Li
Shaomin Li
MJMing Jin
Ming Jin
LLLei Liu
Lei Liu
YDYifan Dang
Yifan Dang
BOBeth L. Ostaszewski
Beth L. Ostaszewski
DSDennis J. Selkoe
Dennis J. Selkoe
Pathologic, biochemical and genetic evidence indicates that accumulation and aggregation of amyloid β-proteins (Aβ) is a critical factor in the pathogenesis of Alzheimer’s disease (AD). Several therapeutic interventions attempting to lower Aβ have failed to ameliorate cognitive decline in patients with clinical AD significantly, but most such approaches target only one or two facets of Aβ production/clearance/toxicity and do not consider the heterogeneity of human Aβ species. As synaptic dysfunction may be among the earliest deficits in AD, we used hippocampal long-term potentiation (LTP) as a sensitive indicator of the early neurotoxic effects of Aβ species. Here we confirmed prior findings that soluble Aβ oligomers, much more than fibrillar amyloid plaque cores or Aβ monomers, disrupt synaptic function. Interestingly, not all (84%) human AD brain extracts are able to inhibit LTP and the degree of LTP impairment by AD brain extracts does not correlate with Aβ levels detected by standard ELISAs. Bioactive AD brain extracts also induce neurotoxicity in iPSC-derived human neurons. Shorter forms of Aβ (including Aβ1–37, Aβ1–38, Aβ1–39), pre-Aβ APP fragments (− 30 to − 1) and N-terminally extended Aβs (− 30 to + 40) each showed much less synaptotoxicity than longer Aβs (Aβ1–42 - Aβ1–46). We found that antibodies which target the N-terminus, not the C-terminus, efficiently rescued Aβ oligomer-impaired LTP and oligomer-facilitated LTD. Our data suggest that preventing soluble Aβ oligomer formation and targeting their N-terminal residues with antibodies could be an attractive combined therapeutic approach.